Hydroxypinacolone Retinoate
Also known as HPR, Granactive Retinoid, Retinoic Acid 3,3-Dimethyl-2-oxobutyl Ester, MDI 101, (3,3-Dimethyl-2-oxobutyl) (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate
“CIR Expert Panel says: not assessed.”
Hydroxypinacolone Retinoate (HPR; CAS 893412-73-2; C26H38O3; FDA UNII NJ3V2F02E1; trade name Granactive Retinoid which is HPR 10% solubilized in 90% Dimethyl Isosorbide) is a third-generation retinoid ester of all-trans retinoic acid with the 3,3-dimethyl-2-oxobutyl (pinacolone) ester group, marketed as a 'direct-acting' retinoid alternative that binds RAR/RXR receptors without requiring the retinol -> retinaldehyde -> retinoic acid metabolic conversion sequence. CIR has NOT issued a safety assessment for Hydroxypinacolone Retinoate — verified absent from the December 2025 CIR QRT (latest version, 481 pages; H-section searched pp. 227-230 with no Pinacolone or HPR entry; no non-Retinol/Retinyl-Palmitate retinoate entries anywhere in the document) and from the September 2022 QRT. The FDA has registered HPR in the UNII Substance Registration System (UNII NJ3V2F02E1) but the registry entry explicitly notes UNII listing 'does not imply any regulatory review or approval'. The peer-reviewed PubMed evidence base (18 indexed records) consists primarily of small open-label or industry-sponsored efficacy/tolerability studies: Veraldi 2015 (PMID 25876142) reports 0.1% HPR gel achieved 41% GAGS reduction in mild-to-moderate acne (n=94 evaluable, 12 weeks) with 15.3% of patients experiencing mild-to-moderate local side effects (dryness, peeling, erythema, burning) — substantially below typical retinoic acid irritation rates but contradicting marketing claims of 'no irritation'. Bettoli 2017 (PMID 26889724) extended this to a 12-month maintenance trial post-isotretinoin (n=39 completers, 6 relapses) with no adverse events reported. Wang 2023 (PMID 36762391) demonstrated synergistic efficacy with retinyl propionate at 5:9 weight ratio in Chinese subjects (8.3% wrinkle reduction, 25.7% TEWL improvement). Shu 2024 (PMID 37990342) head-to-head compared 5 retinoids and found HPR was effective for anti-photoaging but retinyl propionate and retinyl palmitate showed superior antioxidative/anti-inflammatory activity in animal models. Kruger 2025 (PMID 39394831, sponsored by Estee Lauder Companies) reported a 16-week trial in 71 women aged 40-65 showing an HPR-peptide serum achieved parity or statistically superior improvement vs single-session fractional CO2 laser across 10 photoaging parameters. The evidence supports lower-irritation claims relative to retinoic acid (tretinoin) at typical 1-2% commercial use levels, but the 'no irritation' marketing positioning is not consistent with the Veraldi 0.1% acne data. No US FDA Warning Letter targeting HPR specifically was identified, but cosmetic positioning that approaches anti-wrinkle drug claims (the 2018 FDA Warning Letter framework on cosmetic-vs-drug status applies broadly to the retinoid category).
Acts as a direct retinoid receptor (RAR/RXR) agonist without requiring the retinol -> retinaldehyde -> retinoic acid metabolic conversion required by retinol; this eliminates one rate-limiting metabolic step and may explain comparable receptor-binding effects at lower equivalent concentrations than retinol
Documented anti-acne efficacy: Veraldi 2015 showed 0.1% HPR gel produced 41% mean GAGS score reduction in mild-to-moderate acne over 12 weeks (n=94 evaluable); Bettoli 2017 showed maintenance efficacy over 12 months post-isotretinoin with low relapse (15.4%) and good tolerability
Comparable photoaging efficacy to fractional CO2 laser: Kruger 2025 (PMID 39394831, n=71) showed 16-week topical HPR-peptide serum achieved parity or statistical superiority vs single-session fractional CO2 laser across 10 visual signs of photoaging (marionette lines, fine lines, wrinkles, crow's feet, nasolabial folds, texture, smoothness, hyperpigmentation, lift, photodamage) with comparable tolerability
Synergistic with retinyl propionate: Wang 2023 demonstrated optimal in vitro and in vivo anti-aging performance from HPR:RP combinations at 5:9 weight ratio (8.3% wrinkle reduction, 11.9% smoothness improvement, 25.7% TEWL improvement, 14.5%/22.6% R2/R5 elasticity improvement) suitable for sensitive Asian skin types
Higher chemical and photolytic stability than retinol and retinaldehyde — the pinacolone ester group reduces oxidation susceptibility, allowing simpler formulation packaging and longer shelf life
Lower irritation profile than topical retinoic acid (tretinoin) at comparable cosmetic concentrations, supported by industry tolerability data and clinical observations — though 'irritation-free' claims overstate the evidence (see concerns)
Trade name Granactive Retinoid (Grant Industries) is a 10% HPR solubilized in 90% Dimethyl Isosorbide (a penetration enhancer); this delivery system may improve epidermal bioavailability vs neat HPR powder formulations
No CIR safety assessment exists for Hydroxypinacolone Retinoate — verified absent from the December 2025 (latest) and September 2022 CIR Quick Reference Tables; HPR is post-2010 commercial introduction and remains unassessed by the CIR Expert Panel as of April 2026. No SCCS opinion exists. FDA UNII registration is identifier-only and is explicitly documented as not implying regulatory review or approval
Marketing positioning as 'no irritation' or 'irritation-free' retinoid alternative overstates the published evidence: Veraldi 2015 reported 15.3% of patients on 0.1% HPR gel experienced mild-to-moderate local side effects (dryness, peeling, erythema, burning) at the relatively low cosmetic-use concentration; commercial products at 2% or 5% HPR-equivalent (e.g., The Ordinary Granactive Retinoid 2% Emulsion = 0.2% HPR; 5% in Squalane = 0.5% HPR) are likely to produce higher irritation rates than the marketing implies
Most published efficacy literature is industry-sponsored or sponsor-affiliated (Estee Lauder, Grant Industries, Chinese cosmetic R&D groups) with small sample sizes, open-label or non-randomized designs, and proprietary delivery vehicles — evidence quality for the active ingredient itself (separate from delivery system) is moderate, not extensive
Cosmetic claims commonly made for HPR products ('reduces wrinkles', 'reverses signs of aging', 'increases collagen synthesis') approach US FDA structure/function claims that distinguish cosmetics from drugs; the FDA has issued Warning Letters to numerous cosmetic-marketed retinoid products for drug claims under the FDCA cosmetic/drug definition framework — brands marketing HPR products in the US should pre-vet claim language
HPR is metabolized in vivo and chemically related to retinoic acid (the active form of vitamin A); pregnancy-category caution that applies to topical retinoids generally is appropriate for HPR despite the cosmetic-vs-drug distinction. The retinoid drug class includes known teratogens (oral isotretinoin; topical tretinoin Category C); cosmetic-grade HPR has not been studied for systemic absorption or pregnancy safety in cosmetic dose ranges
Cumulative vitamin A exposure from cosmetic retinoids is regulated by EU SCCS at 0.05% Retinol Equivalent (RE) for body lotion / 0.3% RE for other leave-on per Regulation 2024/996 Annex III entry 376 — retinoates contribute to total RE intake but the specific RE conversion factor for HPR has not been published; EU compliant formulations using HPR should account for cumulative RE if combined with other vitamin A esters
Distinct from prescription retinoic acid (tretinoin), which is regulated as an OTC drug in the US (ANDA-required); HPR is the cosmetic-grade ester variant. Consumer confusion conflating 'retinoid' with 'retinoic acid' may lead to off-label use patterns or expectations that exceed cosmetic-grade efficacy